samidorphan (Lybalvi) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Samidorphan is an opioid antagonist that in the form of olanzapine/samidorphan is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth.   Wikipedia

Chemistry

  • SMILES: NC(=O)c1ccc2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)c2c1O
  • InChIKey: RYIDHLJADOKWFM-MAODMQOUSA-N
  • Mol. Mass: 370.45
  • ALogP: 1.25
  • ChEMBL Molecule:
    samidorphan  
More Chemistry

Pharmacology

Combination drugs

( samidorphan (Lybalvi), olanzapine (zyprexa) )

Alternative names

3-carboxamido-4-hydroxynaltrexone | alk3831 | alks33 | alks 33 | alks-33 | alks 3831 | rdc-0313 | rdc-0313-00 | samidorphan

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (2)


 

Bipolar Disorder (approved 2021)

Schizophrenia (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Alcoholism (Phase 2)

Binge-Eating Disorder (Phase 2)

Bipolar Disorder (Phase 3)

Cocaine-Related Disorders (Phase 1)

Depression (Phase 3)

Depressive Disorder, Major (Phase 3)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Pharmacokinetics (Phase 1)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 37
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue